Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02507232
Recruitment Status : Recruiting
First Posted : July 23, 2015
Last Update Posted : May 20, 2019
Sponsor:
Collaborator:
NovoCure Ltd.
Information provided by (Responsible Party):
Santosh Kesari, John Wayne Cancer Institute

Brief Summary:
The purpose of this study is to test the effectiveness and safety of the NovoTTF-200A device in patients with low-grade glioma when it's used by itself or used together with temozolomide. Researchers would also like to know whether the use of NovoTTF-200A, with or without temozolomide, is associated with fewer negative side effects on mental function that may be seen with other currently used treatment options.

Condition or disease Intervention/treatment Phase
Glioma Device: NovoTTF-200A Drug: Temozolomide Early Phase 1

Detailed Description:

Approximately 2,000 to 3,000 low-grade gliomas (LGGs) are diagnosed in adults each year in the United States. Based on a variety of prognostic factors the median overall survival ranges from 3 to 9 years.

NovoTTF-200A is a device that produces alternating electrical fields within the human body that disrupt cell division. These very low intensity intermediate frequency electric fields (TTFields) impair the growth of tumor cells through the arrest of cell division and inducing apoptosis.

Although FDA approved for the treatment of recurrent or progressive glioblastoma, further investigation of NovoTTF-200A is warranted, in the setting of low-grade glioma where it has the potential to stunt tumor growth without significant toxicity. NovoTTF-200A has also been shown to be safe combined with adjuvant 5-day temozolomide regimen in newly diagnosed glioblastoma in an ongoing clinical trial. Given the low proliferative index in low-grade gliomas, combining NovoTTF-200A with metronomic chemotherapy may be more effective.

This is a randomized, 2-arm, open label study of NovoTTF-200A alone or combined with daily temozolomide for the treatment of patients with newly diagnosed low-grade gliomas.

Patients will be randomized 1:1 to one of two arms for a total of 22 patients (11 per arm). Arm A will receive NovoTTF-200A only and Arm B will receive NovoTTF-200A and low-dose (50 mg/m2) daily temozolomide regimen.

All patients providing informed consent will be screened for eligibility. Baseline assessments will include vital signs, physical exam, blood hematology and chemistries, Karnofsky Performance Status (KPS) evaluation, Quality of Life (QOL) assessment using the Functional Assessment of Cancer Therapy-Brain (FACT-Br), a neurological exam and neuro-imaging (MRI) of brain. An extra blood sample will be collected for biomarker studies.

Clinical evaluations include physical exam, vitals, KPS, neurological exam and blood hematology and chemistries (obtained once every month throughout treatment). Neuro-imaging and assessment for response will be performed approximately every 3 months. QOL will be assessed with the KPS rating scale and the FACT-Br questionnaire at screening and then every six months during treatment. Blood will be collected for correlative studies on Day 1 of every even cycle. Any molecular information derived from the correlative studies or clinical care will be associated with the patient's response.

Patients will continue monthly cycles of treatment for 12 cycles or until disease progression or unacceptable toxicity (whichever occurs first). For those in Arm B, patients may continue NovoTTF-200A treatment if temozolomide is discontinued early for toxicity. An end of treatment visit for clinical evaluations and safety assessments will be performed approximately four to six weeks of withdrawing from study treatment. Patients discontinuing study treatment will be followed at months 18 and 24 with tumor assessments if they discontinued from study treatment without disease progression and for survival.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Randomized Study of NovoTTF-200A Alone and Combined With Temozolomide in Patients With Low-Grade Gliomas
Actual Study Start Date : April 17, 2017
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : April 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Arm A
NovoTTF-200A
Device: NovoTTF-200A
12 cycles

Active Comparator: Arm B
NovoTTF-200A + Temozolomide 50 mg/m2 daily (oral)
Device: NovoTTF-200A
12 cycles

Drug: Temozolomide
50 mg/m2/day rounded to the nearest 5 mg. One cycle is 28 days and will be given for 12 cycles
Other Name: Temodar




Primary Outcome Measures :
  1. Toxicity associated with treatment with NovoTTF-200A alone and combined with temozolomide [ Time Frame: 24 months ]
    Participants will be assessed for the development of toxicity according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE), version 4.03. Dose adjustments will be made according to the system showing the greatest degree of toxicity.


Secondary Outcome Measures :
  1. Efficacy of NovoTTF-200A alone and combined with temozolomide [ Time Frame: 24 months ]
    Participants will be assessed for efficacy of NovoTTF-200A alone and combined with temozolomide as measured by progression free survival (PFS), overall survival (OS), and tumor responses over 24 months.

  2. 12-month objective response rate (ORR) of NovoTTF-200A alone and combined with temozolomide [ Time Frame: 12 months ]
    Participants will be assessed for 12-month objective response rate (ORR) of NovoTTF-200A alone and combined with temozolomide in the treatment of adults with newly diagnosed low grade glioma.

  3. Effects of NovoTTF-200A alone and combined with temozolomide on seizure activity [ Time Frame: 24 months ]
    Participants will be assessed for seizure frequency.

  4. Effects of NovoTTF-200A alone and combined with temozolomide on quality of life (QOL) [ Time Frame: 24 months ]
    Participants will be assessed for quality of life using the FACT-Br questionnaire.

  5. Frequency of transformation from low-grade glioma into high-grade glioma [ Time Frame: 24 months ]
    Glioma tumor grade will be assessed over time for transformation to a higher grade.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed low-grade glioma including astrocytoma grade 2, oligodendroglioma grade 2, or oligoastrocytoma grade 2.
  • Tumor is supratentorially located and measureable.
  • Disease that has not received prior radiation, radiosurgery, chemotherapy, or other investigational treatment directed at the brain tumor at any time. Previous surgical procedures is allowed.
  • Age ≥ 18 years.
  • Life expectancy > 12 weeks.
  • Either not receiving steroids for disease symptoms or are on stable dose of steroids for at least 5 days.
  • Karnofsky Performance Status (KPS) ≥ 60%
  • Adequate hematologic function evidenced by:

    • Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
    • Platelet count ≥ 100 x 109/L
    • Hemoglobin ≥ 9.0 g/dL
  • Adequate renal function evidenced by:

    • AST/SGOT and ALT/SPGT ≤ 2.5 X institutional upper limit of normal
    • Total bilirubin ≤ 1.5 x institution's ULN
    • Serum creatinine ≤ 1.5 x institution's ULN

Exclusion Criteria:

  • Pilocytic astrocytoma, ganglioglioma, pleomorphic xanthastrocytoma, or dysembryoplastic neuroepithelial tumors are not eligible.
  • Current or anticipated use of other investigational agents.
  • Implanted electronic medical device in the brain (e.g., deep brain stimulator, vagus nerve stimulator, programmable shunt).
  • Patients who are less than 4 weeks from surgery or have insufficient recovery from surgical-related trauma or wound healing.
  • Severe or uncontrolled medical disorder that would, in the investigator's opinion, impair ability to receive study treatment (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary disease or active, uncontrolled infection, psychiatric illness/social situations that would limit compliance with study requirements).
  • Severe cardiac insufficiency (NYHA III or IV), with uncontrolled and/or unstable cardiac or coronary artery disease.
  • Pregnant or nursing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02507232


Contacts
Layout table for location contacts
Contact: Jaya Gill, RN 310-582-7437 jaya.gill@providence.org
Contact: Neuro-Oncology Team 310-825-8265 neuro.oncology@jwci.org

Locations
Layout table for location information
United States, California
John Wayne Cancer Institute Recruiting
Santa Monica, California, United States, 90404
Sponsors and Collaborators
Santosh Kesari
NovoCure Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Santosh Kesari, MD, PhD John Wayned Cacner Institute

Layout table for additonal information
Responsible Party: Santosh Kesari, Associate Professor, John Wayne Cancer Institute
ClinicalTrials.gov Identifier: NCT02507232     History of Changes
Other Study ID Numbers: JWCI-16-1101
First Posted: July 23, 2015    Key Record Dates
Last Update Posted: May 20, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No

Keywords provided by Santosh Kesari, John Wayne Cancer Institute:
glioma
temozolomide
brain
NovoTTF-200A
cancer
low-grade glioma

Additional relevant MeSH terms:
Layout table for MeSH terms
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Temozolomide
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents